Longboard Pharmaceuticals: Investor & Analyst Day Focused on the Developmental and Epileptic Encephalopathy (DEE) Landscape and LP352, a First-in-Class 5-HT2C Receptor Superagonist in Development for Seizures Associated with DEEs
| DATE: | October 11, 2023 |
|---|---|
| TIME: | 9:30 AM EDT |
| LOCATION: |
Cooley, LLP, 55 Hudson Yards
New York, 10001 United States |
About The Event
Join us for an in-person event with Longboard Pharmaceuticals, featuring DEE thought leaders who will discuss the unmet medical need and current and emerging treatment landscape for people living with refractory epilepsies.
The Longboard Pharmaceuticals team will discuss the ongoing Phase 1b/2a PACIFIC Study evaluating LP352, an oral, centrally acting 5-HT2C receptor superagonist, as a potential treatment of seizures associated with a broad range of DEEs. The PACIFIC Study is fully enrolled, and topline data are expected around year-end 2023.
A live question and answer session will follow the formal presentations.